0001661181-21-000025.txt : 20210218
0001661181-21-000025.hdr.sgml : 20210218
20210218203413
ACCESSION NUMBER: 0001661181-21-000025
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210216
FILED AS OF DATE: 20210218
DATE AS OF CHANGE: 20210218
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Gillheeney Gary S.
CENTRAL INDEX KEY: 0001757373
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37906
FILM NUMBER: 21651645
MAIL ADDRESS:
STREET 1: C/O ORGANOGENESIS INC.
STREET 2: 85 DAN ROAD
CITY: CANTON
STATE: MA
ZIP: 02021
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Organogenesis Holdings Inc.
CENTRAL INDEX KEY: 0001661181
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 85 DAN ROAD
CITY: CANTON
STATE: MA
ZIP: 02021
BUSINESS PHONE: 781-575-0775
MAIL ADDRESS:
STREET 1: 85 DAN ROAD
CITY: CANTON
STATE: MA
ZIP: 02021
FORMER COMPANY:
FORMER CONFORMED NAME: Avista Healthcare Public Acquisition Corp.
DATE OF NAME CHANGE: 20151215
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2021-02-16
0001661181
Organogenesis Holdings Inc.
ORGO
0001757373
Gillheeney Gary S.
C/O ORGANOGENESIS HOLDINGS INC.
85 DAN ROAD
CANTON
MA
02021
1
1
0
0
President and CEO
Class A Common Stock
2021-02-16
4
A
0
51626
0
A
245845
D
Class A Common Stock
2021-02-17
4
S
0
78201
13.3
D
167644
D
Class A Common Stock
2021-02-17
4
S
0
11174
13.82
D
156470
D
Class A Common Stock
2021-02-18
4
S
0
16663
12.85
D
139807
D
Stock Option (Right to Buy)
13.68
2021-02-16
4
A
0
395289
0
A
2031-02-16
Class A Common Stock
395289
395289
D
Represents a grant of restricted stock units ("RSUs") under the Organogenesis Holdings Inc. ("Organogenesis") 2018 Equity Incentive Plan. Each RSU represents the contingent right to receive, upon vesting of the unit, one share of Organogenesis Class A common stock. The RSUs vest in equal annual installments over four years beginning February 16, 2021.
The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person in August 2020.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.76 to $13.75, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.76 to $13.90, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4.
The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.62 to $13.265, inclusive. The reporting person undertakes to provide to Organogenesis, any security holder of Organogenesis, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4.
The option becomes exercisable in equal annual installments over four years beginning February 16, 2021.
/s/ Stacie S. Aarestad, Attorney-in-Fact
2021-02-18